FDA biologics chief outlines ways to remove barriers to cell and gene therapies
October 13, 2022 -- At this year's Meeting on the Mesa, the U.S. Food and Drug Administration’s top biologics regulator said the use of a “cookbook” for developing cell and gene therapy products and global regulatory convergence could help to facilitate their development and take them to the next level. Read More
New ARM CEO provides vision for cell and gene therapy sector, need to address stakeholder concerns
October 12, 2022 -- Timothy Hunt, the new CEO of the Alliance for Regenerative Medicine (ARM), kicked off the 2022 Cell & Gene Meeting on the Mesa, laying out his vision for the industry and emphasizing the need to engage all major stakeholders. Read More
Panel to focus on pluripotent stem cells at Cell & Gene Meeting on the Mesa
October 11, 2022 -- A panel on October 13 at the Cell & Gene Meeting on the Mesa in Carlsbad, CA, will focus on new pluripotent stem cell (PSC) developments and advancements as well as the challenges of scaling up PSC-derived cell therapies. Read More
Gene therapy one step closer to delivery across blood-brain barrier: study
October 11, 2022 -- Brigham and Women’s Hospital researchers say the rational design of adeno-associated viruses has generated gene therapy delivery vectors that are better at crossing the blood-brain barrier to treat diseases of the central nervous system. Read More
6 startups to compete for $250K grand prize at 2022 BioTools Innovator capstone event
October 10, 2022 -- BioTools Innovator will hold its 2022 capstone event on October 13 in Carlsbad, CA, collocated with the Cell & Gene Meeting on the Mesa. Read More
Cytiva acquires Cevec Pharmaceuticals to boost cell line development
October 10, 2022 -- Life sciences company Cytiva has acquired Cevec Pharmaceuticals for an undisclosed amount, which will further strengthen Cytiva's cell line development, according to the companies. Read More
Meeting on the Mesa comes at pivotal time for cell and gene therapy industry
October 5, 2022 -- Stakeholders from around the cell and gene therapy sector will come together during the Alliance for Regenerative Medicine’s hybrid 2022 Meeting on the Mesa, October 11-13 in Carlsbad, CA, to discuss the opportunities and challenges facing the industry. Read More
FDA creates “Super Office” to manage growing cell and gene therapy workload
October 4, 2022 -- The U.S. Food and Drug Administration (FDA) has elevated and reorganized its Office of Tissues and Advanced Therapies to a “Super Office” within the Center of Biologics Research and Evaluation to meet its growing cell and gene therapy workload. Read More
Mixed bag so far in 2022 for cell and gene therapy sector: ARM report
October 3, 2022 -- So far, 2022 has been a mixed bag for the cell and gene therapy sector on the regulatory and investment fronts, according to a new report from the Alliance for Regenerative Medicine (ARM). Read More
Biotech licenses drug discovery platform from Harvard, Tufts to study complex CNS diseases
September 28, 2022 -- Unravel Biosciences has licensed a drug discovery platform from Harvard University and Tufts University to decode and model complex central nervous system (CNS) diseases. Read More
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter